Amygdala Neurosciences
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
509 Hale St, Palo Alto, California, 9430...Website
www.amygns.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Amygdala Neurosciences
Amygdala Neurosciences is a biopharmaceutical company focused on inventing and developing first-in-class medicines to treat substance use disorders (SUD). The company is leading the discovery and development of ALDH2 inhibitors aimed at helping patients overcome cravings associated with addiction. Their mission emphasizes the treatability of addiction as a chronic disease. Intended clients include individuals struggling with substance misuse and healthcare providers seeking innovative treatment options.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Amygdala Neurosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Amygdala Neurosciences has new funding data
Amygdala Neurosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Amygdala Neurosciences had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Amygdala Neurosciences
Check if Amygdala Neurosciences has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Amygdala Neurosciences recently announced quarterly report
Product Launch: Get notified when Amygdala Neurosciences launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Amygdala Neurosciences is spiking on competitors!
Recommended Actions
Find VP level buyers at Amygdala Neurosciences
Find 3 more new buyers
Compare Similar Companies to Amygdala Neurosciences
Compare insights from companies similar to Amygdala Neurosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Amygdala Neurosciences
<$5M
1-10
Private
$5.6M
2015
N/A
Company Profile Activity
Activity Insights
Amygdala Neurosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Amygdala Neurosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Amygdala Neurosciences.
Amygdala Neurosciences financials insights
Gather financial insights about Amygdala Neurosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Other Financing Round
$5.6M
Amygdala Neurosciences Tech Stack
A closer look at the technologies used by Amygdala Neurosciences
Amygdala Neurosciences News & Media
Amygdala Neurosciences Selects ANS-858 for Clinical Development as a Novel ALDH2 Inhibitor for Substance Use Disorder
The discovery and preclinical efficacy of ANS-858, a proprietary, selective, reversible, orally bioavailable ALDH2 inhibitor will be presented at 48th Annual Scientific Meeting of the Research Society on Alcohol. SAN FRANCISCO, April 2, 2025 /PRNewswire/ -- Amygdala Neurosciences, Inc., a...ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder
ANS-858 is a new selective, reversible, orally bioavailable ALDH2 Inhibitor in pre-clinical development to reduce craving. BEL AIR, Md. and SAN FRANCISCO, May 14, 2024 /PRNewswire/ -- Amygdala Neurosciences (a private company) announced today that the Company has closed a new round of...Amygdala Neurosciences Awarded $2.0 million NIH Grant to Conduct IND Enabling Studies
ANS-858, a new selective ALDH2 Inhibitor in pre-clinical development to reduce craving and relapse for patients being treated for alcohol and other substance use disorders. SAN FRANCISCO, Aug. 1, 2023 /PRNewswire/ -- Amygdala Neurosciences (a private company) has been awarded a $2.0...Amygdala Neurosciences Raises $5.6M in Financing
Amygdala Neurosciences, Inc., a San Francisco, CA-based company developing pharmacotherapies to address need associated with substance use disorder, raised $5.6m in funding. The company intends to use the funds to conduct Phase 2 clinical studies to assess ANS-6637 as a treatment for opioid, alcohol, and smoking/nicotine use disorders. The development of its lead compound ANS-6637 […] The post Amygdala Neurosciences Raises $5.6M in Financing appeared first on FinSMEs.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Amygdala Neurosciences
Sign Up For FreeTo access detailed company insights
Amygdala Neurosciences is a biopharmaceutical company focused on inventing and developing first-in-class medicines to treat substance use disorders (SUD). The company is leading the discovery and development of ALDH2 inhibitors aimed at helping patients overcome cravings associated with addiction. Their mission emphasizes the treatability of addict... Read More
